Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
"Unless the competent court finally decides this patent is invalid, we will not be able to commercialize JY29-2 (Jiyoutai) before the expiration of this patent," Jiuyuan Gene said in a draft filing to the Hong Kong stock exchange in January
The CMS said it will release additional details on participation in early 2026
Its dual action on GIP and GLP-1 receptors enhances its ability to reduce blood sugar and achieve more significant weight loss compared to semaglutide
4 Retatrutide has none of these yet, and the realistic UK approval window is late 2027 to mid 2028, with NHS access from 2029 at the earliest
The specific fracture risk associated with GLP-1Ra used for obesity treatment has not yet been evaluated
